BioWorld MedTech

Aug. 5, 2015

View Archived Issues

Drugs enter third dimension: First FDA approval in hand, Aprecia looks to alter drug delivery with 3-D printing

Read More

Less is More with MIS Lipoplasty: Lipoplasty market attractive for both small and large players

Read More

Inside the Beltway: IPPS final rule receives mostly favorable reviews for med-tech DRGs

Read More

Daily M&A: Boston Scientific closes $1.65B buy of the AMS Male Urology Portfolio

Read More

Financings: Novacyt secures flexiblefunding, up to 5 million

Read More

HIT Bits: PhysIQ personalized physiology analytics receives FDA clearance

Read More

People in places

Read More

Products

Read More

MDD's Oncology Extra

Read More

Sour IPO Transforms into Sweet JV: Mevion scraps IPO plans but raises $200M and strikes a JV deal with Chinese investors

A proton therapy systems provider has canceled its plans to go public and now plans to form a joint venture (JV) in China supported by a new investment agreement worth up to $200 million. Read More

Resmed finds sleeper opportunity: Resmed wakes up to potential of huge Chinese sleep disorder market

Read More